Αποτελέσματα Αναζήτησης
7 Αυγ 2021 · We did the pivotal ZUMA-3 trial of KTE-X19 CAR T-cell therapy in the largest population of adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia to date.
28 Μαΐ 2021 · Background: ZUMA-3 is a Phase 1/2 multicenter study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult pts with R/R B-ALL. Phase 1 efficacy results at the recommended Phase 2 dose (1×10 6 CAR T cells/kg) were encouraging (Shah et al. ASCO 2019 #7006).
20 Αυγ 2021 · The findings from the Phase II ZUMA-3 have demonstrated that a single infusion of KTE-X19 is associated with a high and durable response rate in heavily pre-treated adult patients with R/R B-cell ALL.
8 Ιουλ 2021 · ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We report the phase 1 results.
26 Μαΐ 2019 · In an interim analysis of Phase 1 of ZUMA-3, we reported manageable safety and encouraging efficacy of KTE-X19; 72% of pts achieved a complete remission (CR) or CR with incomplete bone marrow (BM) recovery (CRi; Wierda et al, ASH 2018. #897). Here, we present end of Phase 1 results.
29 Νοε 2018 · The initial report of Phase 1 of ZUMA-3, the Phase 1/2 trial of KTE-C19 for treatment of relapsed/refractory (R/R) ALL (NCT02614066), has thus far demonstrated promising efficacy among patients infused with KTE-C19, with a 71% complete remission (CR) rate (CR or CR with incomplete hematologic recovery [CRi]), 88% undetectable minimal residual ...
7 Ιουλ 2022 · The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article, we review outcomes from this study and its implications.
